George Kunos Selected Research

anandamide (arachidonylethanolamide)

5/2015	Cannabinoid receptor 1 promotes hepatocellular carcinoma initiation and progression through multiple mechanisms.
12/2012	Circulating anandamide and blood pressure in patients with obstructive sleep apnea.
1/2008	Multiple pathways involved in the biosynthesis of anandamide.
9/2007	Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats.
8/2007	Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity.
9/2006	A biosynthetic pathway for anandamide.
8/2005	Hemodynamic profile, responsiveness to anandamide, and baroreflex sensitivity of mice lacking fatty acid amide hydrolase.
5/2005	Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity.
10/2004	Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension.
8/2004	Cannabinoid antagonist SR-141716 inhibits endotoxic hypotension by a cardiac mechanism not involving CB1 or CB2 receptors.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

George Kunos Research Topics

Disease

24	Obesity 10/2020 - 05/2005
19	Insulin Resistance 01/2022 - 06/2008
11	Fibrosis (Cirrhosis) 01/2021 - 06/2006
10	Inflammation (Inflammations) 01/2021 - 04/2008
9	Non-alcoholic Fatty Liver Disease 01/2022 - 01/2017
9	Fatty Liver 01/2020 - 07/2003
8	Body Weight (Weight, Body) 01/2019 - 05/2008
8	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2015 - 09/2006
7	Type 2 Diabetes Mellitus (MODY) 10/2020 - 12/2012
7	Liver Cirrhosis (Hepatic Cirrhosis) 03/2018 - 07/2004
7	Hypotension (Low Blood Pressure) 09/2007 - 12/2002
6	Dyslipidemias (Dyslipidemia) 10/2020 - 09/2008
5	Hypertension (High Blood Pressure) 12/2012 - 10/2004
4	Abdominal Obesity 12/2019 - 06/2008
4	Hyperglycemia 01/2019 - 09/2008
4	Hepatocellular Carcinoma (Hepatoma) 01/2017 - 06/2008
4	Liver Diseases (Liver Disease) 01/2011 - 02/2008
3	Endotoxemia 08/2021 - 08/2004
3	Neoplasms (Cancer) 05/2021 - 09/2006
3	Pulmonary Fibrosis (Fibrosing Alveolitis) 01/2020 - 04/2017
3	Cardiovascular Diseases (Cardiovascular Disease) 01/2018 - 10/2008
3	Alcoholic Fatty Liver 01/2018 - 03/2008
3	Weight Loss (Weight Reduction) 08/2012 - 09/2007
3	Cardiomyopathies (Cardiomyopathy) 01/2011 - 10/2005
2	Pathologic Processes 05/2021 - 01/2008
2	Idiopathic Pulmonary Fibrosis 01/2020 - 04/2017
2	Alcoholic Liver Diseases (Alcoholic Liver Disease) 11/2019 - 04/2008
2	Diabetic Nephropathies (Diabetic Nephropathy) 01/2018 - 12/2014
2	Anxiety Disorders (Anxiety Disorder) 05/2016 - 09/2006
2	Weight Gain 10/2015 - 01/2015
2	Glucose Intolerance 11/2013 - 08/2013
2	Alcoholism (Alcohol Abuse) 09/2013 - 04/2002
2	Pain (Aches) 05/2013 - 07/2007
2	Stroke (Strokes) 08/2007 - 09/2006
2	Neuralgia (Stump Neuralgia) 07/2007 - 09/2006
1	COVID-19 01/2022
1	Catalepsy 08/2021
1	Hypothermia 08/2021
1	Mitochondrial Diseases (Mitochondrial Disease) 01/2021
1	Breast Neoplasms (Breast Cancer) 01/2020
1	Hyperinsulinism (Hyperinsulinemia) 01/2019
1	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2019
1	Interstitial Nephritis (Tubulointerstitial Nephritis) 10/2018
1	Hyperammonemia 10/2018

Drug/Important Bio-Agent (IBA)

47	EndocannabinoidsIBA 01/2022 - 04/2002
17	CB1 Cannabinoid Receptor (CB1 Receptor)IBA 12/2019 - 11/2003
17	CannabinoidsIBA 11/2019 - 04/2002
12	Glucose (Dextrose)FDA LinkGeneric 10/2019 - 09/2007
12	anandamide (arachidonylethanolamide)IBA 05/2015 - 12/2002
7	LeptinIBA 10/2017 - 09/2007
7	Cannabinoid Receptors (Cannabinoid Receptor)IBA 04/2017 - 04/2002
7	Insulin (Novolin)FDA Link 01/2015 - 09/2007
6	JD5037IBA 08/2021 - 08/2012
6	Pharmaceutical PreparationsIBA 05/2021 - 06/2008
5	RimonabantIBA 08/2021 - 11/2003
5	Ethanol (Ethyl Alcohol)IBA 03/2018 - 04/2002
5	LipidsIBA 11/2017 - 09/2008
4	Bleomycin (Blenoxane)FDA LinkGeneric 01/2021 - 04/2017
4	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 10/2020 - 07/2016
4	EnzymesIBA 10/2020 - 06/2008
4	Fatty Acids (Saturated Fatty Acids)IBA 01/2019 - 05/2005
3	MRI-1867IBA 08/2021 - 01/2021
3	CytokinesIBA 01/2021 - 04/2008
3	Interleukin-6 (Interleukin 6)IBA 01/2021 - 07/2003
3	Triglycerides (Triacylglycerol)IBA 10/2020 - 09/2007
3	CB2 Cannabinoid ReceptorIBA 01/2019 - 08/2007
3	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2019 - 12/2017
3	LigandsIBA 01/2018 - 05/2005
3	Hormones (Hormone)IBA 02/2014 - 05/2008
2	Nitric Oxide Synthase (NO Synthase)IBA 01/2021 - 01/2020
2	ATP-Binding Cassette Transporters (ABC Transporters)IBA 01/2021 - 01/2020
2	Interleukin-22 (IL-22)IBA 01/2020 - 01/2015
2	Proteins (Proteins, Gene)FDA Link 01/2020 - 01/2015
2	glyceryl 2-arachidonate (2-arachidonoylglycerol)IBA 11/2019 - 12/2002
2	Adrenergic Agents (Adrenergic Drugs)IBA 08/2017 - 09/2007
2	Fatty Acid Synthases (Fatty Acid Synthase)IBA 01/2017 - 04/2008
2	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 10/2015 - 08/2007
2	Nonesterified Fatty Acids (NEFA)IBA 10/2015 - 02/2014
2	AM 251 (AM251)IBA 01/2015 - 08/2004
2	GlucocorticoidsIBA 01/2015 - 06/2008
2	AdiponectinIBA 02/2014 - 09/2007
2	EndotoxinsIBA 04/2010 - 09/2006
2	Sterol Regulatory Element Binding Protein 1IBA 04/2008 - 05/2005
1	Interleukin-6 Receptors (Interleukin 6 Receptor)IBA 01/2021
1	Interleukin-11 (Interleukin 11)IBA 01/2021
1	Hydroxyproline (4 Hydroxyproline)IBA 01/2021
1	indium-bleomycinIBA 01/2021
1	HDL CholesterolIBA 10/2020
1	Mitochondrial DNA (mtDNA)IBA 01/2020
1	Glycoproteins (Glycoprotein)IBA 01/2020
1	ArrestinsIBA 10/2019
1	Mechanistic Target of Rapamycin Complex 2IBA 01/2019
1	CC ChemokinesIBA 01/2019
1	Sirtuin 1IBA 01/2019

Therapy/Procedure

4	Drug Therapy (Chemotherapy) 01/2022 - 11/2008
2	Therapeutics 01/2021 - 07/2003
2	Glycemic Control 01/2019 - 02/2014
2	Intravenous Injections 01/2018 - 08/2004
2	Ligation 07/2016 - 06/2015
1	Subcutaneous Injections 01/2021